Funding sources: none
Conflicts of Interest: EGY is an employee of Mount
Sinai and has received research funds (grants paid to the institution)
from: Abbvie, Amgen, Asana BioSciences, AstraZeneca, Akari, AnaptysBio,
Boehringer-Ingelheim, Eli Lilly, Galderma, Ichnos Sciences, Innovaderm
Research, Janssen, Kiniksa, Kyowa Kirin, Leo Pharma, Novartis, Pfizer,
RAPT Therapeutics, Regeneron Pharmaceuticals, Sienna Biopharma, UCB,
Union Therapeutics; and is a consultant for Abbvie, Almirall, Amgen,
Arena Pharmaceuticals, Asana BioSciences, AstraZeneca, Aslan
Pharmaceuticals, Bristol Myers Squibb, Boehringer-Ingelheim, Cara
Therapeutics, Castle Biosciences, DBV Technologies, DS Biopharma, Eli
Lilly, Evommune, Galderma, Genzyme Corporation, GSK, Ichnos Sciences,
Incyte, Janssen, Kyowa Kirin, Leo Pharma, Novan, Novartis, RAPT
Therapeutics, Sanofi, Sato Pharmaceutical, Siolta, Union Therapeutics,
and Ventyx. RB is an Advisory Board Member, Consultant, Speaker
and/or Investigator for and receives honoraria and/or grant from AbbVie,
Arcutis, Arena Pharma, Aristea, Asana BioSciences, Bellus Health,
Bluefin Biomedicine, Boehringer-Ingelheim, CARA, Dermavant, Eli Lilly,
EMD Serono, Evidera, Galderma, GSK, Inmagene Bio, Incyte, Kiniksa, Kyowa
Kirin, LEO Pharma, Novan, Pfizer, Ralexar, RAPT, Regeneron, Respivant,
Sanofi-Genzyme, Sienna and Target RWE. He is also an employee and
shareholder of Innovaderm Research. ESCP has served as an
advisory board member, consultant, speaker and/or investigator and
received honoraria and/or grants from AbbVie, Arcutis, Arena Pharma,
Aristea, Asana BioSciences, Bellus Health, Boehringer Ingelheim,
Bristol-Myers Squibb, CARA, Celgene, Dermavant, Eli Lilly, Galderma,
GlaxoSmithKline, Incyte, Kiniksa, LEO Pharma, Neokera, Pfizer,
Regeneron, Sanofi-Genzyme, Sienna, Target RWE, and UCB Pharma. All other
authors have no conflict of interest within the scope of the submitted
work.